Co-Diagnostics receives grant of Australian Patent covering Co-Dx PCR tech

Co-Diagnostics (CODX) announced that the Australian Patent Office has granted Australian Patent No. AU2022270084A1, strengthening Co-Dx’s intellectual property portfolio surrounding its novel Co-Dx PCR platform. “This patent represents another significant milestone in securing global protection for our technology as we continue expanding the potential applications of the point-of-care PCR platform,” said Dwight Egan, CEO of Co-Dx. “From the beginning, Co-Dx’s goal has been to make accurate, accessible PCR testing available where it is needed most, and strengthening our global IP portfolio is essential to that mission.”